118 related articles for article (PubMed ID: 38419250)
41. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
42. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
44. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
45. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
46. The management impact of
Kulkarni M; Hughes S; Mallia A; Gibson V; Young J; Aggarwal A; Morris S; Challacombe B; Popert R; Brown C; Cathcart P; Dasgupta P; Warbey VS; Cook GJR
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):674-686. PubMed ID: 31872280
[TBL] [Abstract][Full Text] [Related]
47. Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT.
Lu Y; Li C
Clin Nucl Med; 2022 Dec; 47(12):1103-1104. PubMed ID: 35835124
[TBL] [Abstract][Full Text] [Related]
48. Flare on [
Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
[TBL] [Abstract][Full Text] [Related]
49. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
[TBL] [Abstract][Full Text] [Related]
50. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
51. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
Song R; Jeet V; Sharma R; Hoyle M; Parkinson B
Pharmacoeconomics; 2022 Aug; 40(8):807-821. PubMed ID: 35761117
[TBL] [Abstract][Full Text] [Related]
52. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
[TBL] [Abstract][Full Text] [Related]
53. Penile secondary lesions: a rare entity detected by PET/CT.
Davidson T; Domachevsky L; Giladi Y; Fridman E; Dotan Z; Rosenzweig B; Leibowitz R; Ben Shimol J
Sci Rep; 2021 Mar; 11(1):5912. PubMed ID: 33723317
[TBL] [Abstract][Full Text] [Related]
54. Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.
Davidson T; Amit U; Saad A; Hahiashvili M; Goshen E; Portnoy O; Berger R; Goldstein A; Sadetsky I; Weizman N; Chikman B; Dotan Z; Lawrence YR; Ben-Haim S; Symon Z; Goldstein J
Nucl Med Commun; 2019 Sep; 40(9):913-919. PubMed ID: 31343612
[TBL] [Abstract][Full Text] [Related]
55. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
56.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
57. Perineum and penile invasion of recurrent prostate carcinoma shown by Ga-68 PSMA PET/CT.
Koc ZP; Özcan PP; Erçolak V
Indian J Cancer; 2021; 58(1):101-103. PubMed ID: 33402554
[TBL] [Abstract][Full Text] [Related]
58. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T
Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414
[TBL] [Abstract][Full Text] [Related]
59. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
60. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
